| Literature DB >> 33832057 |
Zhichao Xing1, Yuxuan Qiu1,2, Yuan Fei1, Baoying Xia1, Munire Abuduwaili1, Jingqiang Zhu1, Anping Su1.
Abstract
ABSTRACT: Parathyroid protection during thyroid lobectomy was not illustrated previously. Aim of this study was to find out the influence of parathyroid glands in situ preservation and autotransplantation on postoperative parathyroid function in thyroid lobectomy.Consecutive patients who underwent primary thyroid lobectomy with unilateral central neck dissection for papillary thyroid carcinoma in our center were included retrospectively. Postoperative hypoparathyroidism was defined as low parathyroid hormone (PTH) levels (<1.6 pmol/L) and keeping over 6 months was defined as permanent. Patients were divided into 3 groups: all identified parathyroid glands preserved in situ (preservation group); at least one parathyroid gland autotransplanted without accidental resection (autotransplantation group); at least one parathyroid gland accidental resected (resection group).A total of 425 patients were included. No permanent hypoparathyroidism was reported, and the rates of transient hypoparathyroidism were similar among all groups. Significantly lower serum PTH levels were found in autotransplantation group versus preservation group at postoperative 1-day (3.77 ± 1.61 vs 4.72 ± 2.31, P < .001). Transient hypoparathyroidism was significantly associated with reduced intraoperative carbon nanoparticles utilization (57.1% vs 77.4%, P = .039).Thyroid lobectomy was a safe surgical method for parathyroid protection no matter the practice to ipsilateral parathyroid glands. However, preservation of all parathyroid glands was still recommended considering relatively stable PTH levels.Entities:
Mesh:
Year: 2021 PMID: 33832057 PMCID: PMC8036091 DOI: 10.1097/MD.0000000000021323
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Flow chart of patients reviewed. PTC = papillary thyroid carcinoma, TT = total thyroidectomy, UCND = unilateral central neck dissection.
Demographics and baseline characteristics of patients.
| Preservation group (n = 149) | Autotransplantation group (n = 263) | Resection group (n = 13) | |||
| Age, y | 42.34 ± 11.34 | 40.37 ± 10.82 | 44.92 ± 15.22 | .082 | .307 |
| Sex, male/female | 54/95 | 71/192 | 4/9 | .050 | 1.000 |
| BMI, kg/m2 | 22.83 ± 3.07 | 22.81 ± 3.52 | 22.97 ± 4.57 | .940 | .874 |
| NG | 27/149 | 44/263 | 4/13 | .719 | .353 |
| HD | 17/149 | 47/263 | 3/13 | .082 | .915 |
| GD | 0/149 | 1/263 | 0/13 | 1.000 | 1.000 |
| Hypertension | 12/149 | 26/263 | 3/13 | .537 | .293 |
| Diabetes | 3/149 | 6/263 | 1/13 | 1.000 | .758 |
| Hypothyroidism | 2/149 | 6/263 | 1/13 | .770 | .758 |
| Hyperthyroidism | 3/149 | 2/263 | 0/13 | .517 | 1.000 |
| Largest tumor size, mm | 8.53 ± 5.14 | 8.71 ± 4.93 | 11.35 ± 8.96 | .744 | .112 |
| Multifocality | 20/149 | 38/263 | 1/13 | .774 | .783 |
| Capsule invasion | 9/149 | 23/263 | 2/13 | .324 | .750 |
| Carbon nanoparticles | 85/103 (82.5%) | 98/200 (49.0%) | 5/11 (45.5%) | <.001‡ | .819 |
| TNM stage | |||||
| T1a/T1b/T2 | 118/12/11 | 210/33/13 | 10/1/2 | .261 | .373 |
| Preoperative PTH, pmol/L | 6.12 ± 2.34 | 6.19 ± 3.69 | 8.53 ± 6.21 | .848 | .201 |
| Preoperative calcium, mmol/L | 2.36 ± 0.32 | 2.33 ± 0.14 | 2.41 ± 0.15 | .135 | .061 |
BMI = body mass index, GD = Grave disease, HD = Hashimoto disease, NG = nodular goiter, PTH = parathyroid hormone.
Preservation group versus autotransplantation group.
Autotransplantation group versus resection group.
Means significantly statistical differences.
The details of parathyroid glands function during follow-up.
| Preservation group | Autotransplantation group | Resection group | |||
| No. of identified PGs | 1.84 ± 0.37 | 1.91 ± 0.22 | 1.08 ± 0.49 | .339 | <.001‡ |
| Hypoparathyroidism | |||||
| Transient | 6/136 (4.41%) | 12/165 (7.27%) | 1/13 (7.69%) | .298 | 1.000 |
| Permanent | 0 | 0 | 0 | – | – |
| Postoperative PTH, pmol/L | |||||
| 1 day | 4.72 ± 2.31 | 3.77 ± 1.61 | 4.60 ± 4.66 | <.001‡ | .568 |
| 1 month | 5.41 ± 2.85 | 5.13 ± 1.80 | 6.51 ± 4.78 | .341 | .338 |
| 6 months | 5.28 ± 1.78 | 5.08 ± 1.72 | 6.27 ± 4.51 | .570 | .357 |
No. of identified PGs = number of identified parathyroid glands, PTH = parathyroid hormone.
Preservation group versus autotransplantation group.
Autotransplantation group versus resection group.
Means significantly statistical differences.
Univariate analysis of risk factors for transient hypoparathyroidism.
| Normal | Transient hypoparathyroidism | ||
| Age, y | 41.61 ± 11.43 | 39.19 ± 12.64 | .353 |
| Sex, male/female | 97/204 | 3/18 | .086 |
| BMI, kg/m2 | 23.02 ± 3.59 | 21.51 ± 3.47 | .064 |
| NG | 56/301 | 2/21 | .451 |
| HD | 57/301 | 2/21 | .432 |
| GD | 0/301 | 1/21 | 1.000 |
| Hypertension | 31/301 | 2/21 | 1.000 |
| Diabetes | 8/301 | 1/21 | 1.000 |
| Hypothyroidism | 9/301 | 0/21 | .905 |
| Hyperthyroidism | 4/301 | 1/21 | .751 |
| Largest tumor size, mm | 9.00 ± 5.83 | 8.50 ± 3.34 | .710 |
| Multifocality | 44/301 | 4/21 | .815 |
| Capsule invasion | 22/301 | 0/21 | .403 |
| Carbon nanoparticles | 168/217 (77.4%) | 12/21 (57.1%) | .039∗ |
| TNM stage | |||
| T1a/T1b/T2 | 238/30/22 | 18/0/1 | .118 |
| Preoperative PTH, pmol/L | 6.32 ± 3.82 | 6.35 ± 2.57 | .952 |
| Preoperative calcium, mmol/L | 2.36 ± 0.23 | 2.34 ± 0.16 | .752 |
| No. of identified PGs | 1.86 ± 0.36 | 1.84 ± 0.38 | .856 |
| No. of autotransplanted PGs ≥1 | 159/301 | 13/21 | .420 |
| Accidental parathyroidectomy | 12/301 | 1/21 | 1.000 |
BMI = body mass index, GD = Grave disease, HD = Hashimoto disease, NG = nodular goiter, PGs = parathyroid glands, PTH = parathyroid hormone.
Means significantly statistical differences.
Multivariate analysis of predictors for transient hypoparathyroidism.
| OR | 95% CI | ||
| Female | 2.192 | 0.853–5.632 | .103 |
| BMI <22 kg/m2 | 2.439 | 0.682–8.724 | .170 |
| No carbon nanoparticles | 2.672 | 0.987–7.228 | .053 |
CI = confidence interval, OR = odds ratio.